Keratoacanthoma

    La Roche-Posay
  • May 2022
  • 10min

Therapeutic classes inducing this adverse event
BRAF inhibitor, RAF inhibitor

Keratoacanthoma
Well-defined papule with central hyperkeratotic core, eruptive onset
Well-defined papule with central hyperkeratotic core, eruptive onset

SIMPLIFIED GRADING

Not obvious

<10 lesions


References

Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.

SIMPLIFIED GRADING

Readily apparent

≥10 lesions


References

Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.

Browse for more adverse events